Sotoxen 120 mg (Sotorasib) Tablets | KRAS G12C Mutated NSCLC Therapy

Disclaimer: The following information is provided for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your oncologist or other qualified healthcare provider regarding medical conditions or treatment protocols. (Medically Reviewed By: Dr. Salma Elreedy)

Sotoxen 120 mg, containing the active pharmaceutical ingredient sotorasib, is a first-in-class oral therapy and the generic equivalent of the innovator brand, Lumakras. It is specifically engineered to target a genetic signature in lung cancer once thought “undruggable”: the KRAS G12C mutation. For patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor this specific mutation, Sotoxen provides a precision-medicine pathway. By locking the mutated protein in an inactive state, sotorasib disrupts the signaling that tells cancer cells to grow and spread.

Understanding the Clinical Data

What are the primary clinical indications for Sotoxen 120 mg?

Sotorasib is used to treat adult patients with KRAS G12C mutated non-small cell lung cancer, as established by the FDA and EMA:

• Metastatic NSCLC: Indicated for adult patients with locally advanced or metastatic non-small cell lung cancer.
• KRAS G12C Mutation: The tumor must be confirmed to have a Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation via an approved companion diagnostic test.

Prior Treatment: It is indicated for patients who have received at least one prior systemic therapy (such as chemotherapy or immunotherapy) for their cancer.

How does sotorasib target the cancer at a molecular level?

The KRAS protein normally acts as a biological “on/off” switch for cell growth. In the G12C mutation, the switch is stuck in the “on” position, driving uncontrolled cell division. Sotorasib is a highly selective inhibitor that targets the unique cysteine residue of the KRAS G12C protein.

It binds covalently and irreversibly to the protein when it is in its inactive GDP-bound state. This effectively “locks” the protein in the off position, preventing it from activating downstream pathways like RAF/MEK/ERK. This targeted inhibition leads to cell cycle arrest and apoptosis (cell death) specifically in tumor cells with the G12C mutation.

What is the recommended dosage and administration?

The standard clinical dose for sotorasib is 960 mg taken orally once daily. Since Sotoxen is a 120 mg tablet, this means taking eight tablets at the same time each day.

• Administration: You can take Sotoxen with or without food.
• Practical Tips: Swallow the tablets whole. Do not crush, chew, or split them. If you have difficulty swallowing, tablets can be dispersed in 120 mL (4 oz) of non-carbonated water (without crushing) and consumed within 2 hours.
• Missed Doses: If a dose is missed by more than 6 hours, skip it and take your next dose at the regular time the next day. If you vomit after taking a dose, do not take an extra one; simply wait for the next scheduled dose.

What does the clinical evidence show regarding its effectiveness?

The authority of sotorasib is grounded in the CodeBreaK 100 and CodeBreaK 200 trials, documented on ClinicalTrials.gov and published in the New England Journal of Medicine (NEJM):

• Response Rates: In the pivotal Phase 2 trial (CodeBreaK 100), sotorasib demonstrated a confirmed Objective Response Rate (ORR) of 36% to 41% in heavily pre-treated patients.
• Duration of Response: The median Duration of Response (DOR) was approximately 10 to 12.3 months.
• Disease Control: The disease control rate (DCR) reached over 80%, meaning the cancer either shrank or remained stable for a significant period.

Safety, Side Effects, and Monitoring

What are the potential side effects associated with treatment?

Based on safety reporting from the FDA and EMA, sotorasib has a defined profile requiring proactive medical oversight:

Common Adverse Reactions (Occurring in ≥20% of patients):

• Gastrointestinal Issues: Diarrhea (very common), nausea, and vomiting.
• Musculoskeletal: Pain in the muscles, bones, or joints.
• Constitutional: Fatigue and cough.
• Laboratory Changes: Decreased hemoglobin (anemia) and changes in liver function tests.

Significant Clinical Risks requiring monitoring:

• Hepatotoxicity: Sotorasib can cause drug-induced liver injury. Liver function tests (ALT, AST, and total bilirubin) are required before starting, every 3 weeks for the first 3 months, and then monthly thereafter.
  +1
• Interstitial Lung Disease (ILD)/Pneumonitis: Rare but serious lung inflammation. Tell your oncologist immediately if you develop new or worsening shortness of breath, cough, or fever.
• Drug Interactions: Avoid taking Sotoxen with acid-reducing agents (like PPIs or H2 blockers), as they can lower the drug’s absorption. If an antacid is necessary, take Sotoxen 4 hours before or 10 hours after.

Storage Data and Environmental Stability

Sotoxen 120 mg tablets are stable at room temperature and do not require 2°C to 8°C cold chain refrigeration.

• Standard Storage: Keep at controlled room temperature, 20°C to 25°C (68°F to 77°F).
• Protection: Store in the original container to protect the tablets from light and moisture.

Transit Integrity: Certified pharmaceutical exporters utilize climate-controlled logistics to ensure the medication is not subjected to extreme heat during international transit.

Manufacturer Quality and Trust

Sotoxen is manufactured by Everest Pharmaceuticals, a pioneer in generic oncology. Everest Pharmaceuticals operates under the stringent World Health Organization Good Manufacturing Practices (WHO GMP) standards. Their specialized facility uses high-precision environmental controls and rigorous batch-testing to ensure that every tablet is bioequivalent to the innovator brand (Lumakras), providing the same molecular purity and clinical efficacy as the original.

Global Access to Sotorasib

Accessing specialized lung cancer treatment internationally is a legally governed process. Patients can access Sotoxen 120 mg through verified pharmaceutical exporters under “Personal Use Importation” or “Named Patient” rules.

A valid prescription from a licensed oncologist is a mandatory requirement. This ensures that while patients access affordable generic options, they remain under the professional supervision of their medical team for liver monitoring and safety management.

Frequently Asked Questions (FAQs)

Is Sotoxen 120 mg exactly the same as Lumakras?

Yes. Sotoxen contains sotorasib, the identical active pharmaceutical ingredient as Lumakras. Because it is manufactured under WHO GMP standards, it is clinically bioequivalent, meaning it targets the KRAS G12C mutation with the same mechanism and potency.

What should I do if I develop severe diarrhea?

Diarrhea is a known pharmacological effect. Contact your oncology team; they may suggest starting anti-diarrheal medication or temporarily pausing your dose. Staying hydrated is essential.

Can I take this medicine if I have heart problems?

Unlike some other targeted therapies, sotorasib generally does not carry high cardiovascular warnings. However, always disclose your full medical history to your oncologist before starting.

Why must I avoid grapefruit while taking Sotoxen?

Sotorasib is processed in the liver by the CYP3A enzyme. Grapefruit can interfere with this enzyme, causing the drug levels in your blood to rise significantly, which increases the risk of side effects.

How long does it take for sotorasib to show results?

Individual response varies, but many patients see stabilization or shrinkage on their first set of scans, which are typically performed 6 to 9 weeks after starting the medication.